n
 
About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, December 19th, 2017

The QualityStocks
Daily Stock List

graphic
graphic

MariMed, Inc. (MRMD)

Investors Hub, OTC Markets, and DailyMarijuanaObserver reported on MariMed, Inc. (MRMD), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

MariMed, Inc. is an industry leader in the design, development, operation, funding, and optimization of medical cannabis cultivation and production centers and dispensaries. The Company provides turnkey solutions to cannabis cultivators, producers, and dispensaries. It specializes in solutions for securing and operating facilities, manufacturing and processing, dispensary, layouts, and designs, merchandising and sales. OTCQB-listed, MariMed has its corporate office in Newton, Massachusetts.

MariMed is focusing exclusively on serving the fast expanding $7 billion legal cannabis industry. MariMed reported strong revenue growth for 2016 that continued into 2017. The Company more than doubled revenue in 2016 over 2015, increasing from $1.27 million in 2015 to $3.56 million in 2016. Most of the revenue was attributable to subsidiary MariMed Advisors and its cannabis services and products business.

MariMed is on the vanguard of medical research, working to create precision dosed products to treat specific conditions. Its team has developed state-of-the-art and regulatory compliant facilities in numerous states. These facilities are replicable and scalable models of excellence in horticultural principals, cannabis production, product development, as well as dispensary operations.

The Company provides a complete range of consulting services in the medical cannabis industry. It uses a systematic approach, from the permit and application process, to on-time operational readiness. As Cannabis experts, it specializes in supporting the development of high quality state-licensed, medical cannabis dispensaries and cultivation facilities.

MariMed’s services include application assistance, real estate and safe access, build-out and ongoing consultation, business acceleration solutions, and physician and patient outreach. MariMed Advisors, Inc. has a portfolio of high-quality branded products, product development plans, product packaging, and product licensing opportunities.

In November, MariMed announced that it acquired the rights to the intellectual property (IP), formulations, recipes, proprietary equipment, and expertise of Betty’s Eddies from Icky Enterprises LLC. This acquisition enables MariMed to further expand its inventive, industry-leading Kalm Fusion™ precision dosed medical cannabis-infused product line.

Betty’s Eddies is a line of fruit chews handcrafted and naturally sweetened with the finest all natural ingredients and non-GMO organic fruits and vegetables. MariMed has a licensing agreement where Canuvo, Inc., will manufacture and distribute MariMed Kalm Fusion™ and Betty’s Eddies™ branded medical cannabis products in Maine.

Recently, MariMed announced the purchase of a 137,500 sq. ft. industrial building on 17 acres at 167 John Vertente Blvd., in the New Bedford, Massachusetts industrial park for a purchase price of $6,895,000. MariMed will develop roughly 70,000 sq. ft. into a full service state of the art medical cannabis cultivation and production facility. This has been leased to ARL Healthcare, Inc. (ARL), a Massachusetts not for profit corporation.

MariMed assisted ARL Healthcare in its successful application to be awarded a Massachusetts Registered Marijuana Dispensary (RMD) License for cultivation, production, and dispensing of medical cannabis. MariMed will assist ARL Healthcare in the development and ongoing management of the cultivation and manufacturing facility. ARL expects to start cultivation in Q1 of 2018.

MariMed, Inc. (MRMD), closed Tuesday's trading session at $0.65, up 3.17%, on 36,491 volume with 33 trades. The average volume for the last 60 days is 59,058 and the stock's 52-week low/high is $0.20/$0.835.

Cannabis Wheaton Income Corp. (CBWTF)

Epic Stock Picks, Wealth Daily, Marketwired, OTC Markets, MarketWatch, Barchart, 4-Traders, Investors Hangout, Investopedia, Street Insider, Insider Financial, Investopedia, and Stock of the Week reported on Cannabis Wheaton Income Corp. (CBWTF), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets’ OTCQB, Cannabis Wheaton Income Corp. operates as a cannabis streaming company. Its mandate is to facilitate growth for its partners through providing them with financial support and sharing the Company’s collective industry experience. Cannabis Wheaton invests and supports a broad array of cannabis cultivation companies.

Cannabis Wheaton has its corporate headquarters in Vancouver, British Columbia. Incorporated in 1987, the Company previously went by the name Knightswood Financial Corp. It changed its name to Cannabis Wheaton Income Corp. in May of this year.

Cannabis Wheaton provides financial support for cannabis facility expansions, operations, and initial construction. It does so in exchange for minority equity interests and a portion of the cultivation production. The Company’s partners maintain their brand autonomy. In addition, they gain access to better scaling flexibility.

Cannabis Wheaton’s team has a depth of knowledge from cultivation, regulatory, construction, retail, branding, finance and technology. The Company is using the stream, or streaming model, to finance cannabis companies. It has agreements with over a dozen partners.

This month, Cannabis Wheaton announced it was awarded Startup of the Year at the 2017 Canadian Cannabis Awards gala. Most of the awards were decided by the public.

Moreover, a select committee of industry stakeholders selected winners in the Product of the Year, Lifetime Achievement Award, Top Charitable Initiative, Most Progressive Canadian Researcher, and Startup of the Year categories, as well as many more. Cannabis Wheaton Chairman and Chief Executive Officer, Mr. Chuck Rifici, also won the Innovator of the Year Award.

Recently, Cannabis Wheaton and Beleave, Inc. announced that they, along with Beleave's wholly-owned operating subsidiary, Beleave Kannabis Corp., entered a definitive agreement where Cannabis Wheaton will provide Beleave with up to $10,000,000 in non-dilutive debt financing via an instrument evidencing a debt obligation repayable in product equivalents (the D.O.P.E. Note). The proceeds of the D.O.P.E. Note will be used by Beleave to finance the construction of an expansion facility that will be located next to Beleave's facility outside of Hamilton, Ontario.

Mr. Chuck Rifici, Cannabis Wheaton CEO, said, "We are excited to announce this innovative financing instrument that will help our streaming partner Beleave achieve the non-dilutive capital they seek to further its objectives. The Cannabis Wheaton team is constantly looking for creative solutions to provide additional value to our streaming partners and we view the D.O.P.E. Note as another tool for the company to utilize in furtherance of that goal.”

Last month, Cannabis Wheaton announced the closing of the acquisition of all of the issued and outstanding shares of RockGarden Medicinals (2014), Inc. pursuant to the terms of a definitive share purchase agreement dated October 31, 2017.

This acquisition furthers Cannabis Wheaton’s streaming platform strategy through providing the Company more resources and regulatory tools to help speed up Wheaton Licensing Program participants' pathway to licensing under the Access to Cannabis for Medical Purposes Regulations (ACMPR). RockGarden is a privately owned licensed producer of cannabis pursuant to the ACMPR. RockGarden was granted a cultivation license on August 25, 2017.

Cannabis Wheaton Income Corp. (CBWTF), closed Tuesday's trading session at $0.82739, up 10.60%, on 3,064,175 volume with 1,907 trades. The average volume for the last 60 days is 253,158 and the stock's 52-week low/high is $0.5213/$2.3614.

Delcath Systems, Inc. (DCTH)

OTC Markets, Barchart, Invest, Morningstar, Stock News Journal, Stocktwits, SuperStockScreener, TradingView, MarketWatch, StocksGallery, 4-Traders, and Insider Financial reported on Delcath Systems, Inc. (DCTH), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Delcath Systems, Inc. is an interventional oncology Company focused on the treatment of primary and metastatic liver cancers. The Company’s investigational product is Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The design of this product is to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Delcath Systems is based in New York City.

The Company’s system has been commercially available in Europe since 2012 under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), where it has been used at major medical centers to treat a wide variety of cancers of the liver. Liver directed high dose chemotherapy utilizes percutaneous hepatic perfusion (PHP) to deliver concentrated doses of a chemotherapeutic agent directly to the liver.

Delcath Systems has supported clinical research of liver directed high dose chemotherapy in patients with metastatic ocular and cutaneous melanoma, metastatic colorectal cancer, metastatic neuroendocrine tumors, and hepatocellular carcinoma.

The Company has commenced a global Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma (OM). Delcath plans to initiate an international registration trial for intrahepatic cholangiocarcinoma (ICC). Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S.

Delcath Systems is working on advancing its clinical programs of its innovative Melphalan/HDS. Additionally, it is working to drive commercialization efforts for CHEMOSAT in Europe. The Company continues its concentration on the clinical trials that consists of the Clinical Development Program (CDP).

The Company’s CDP consists of its FOCUS Phase 3 clinical trial of Melphalan/HDS in hepatic dominant OM (the FOCUS trial). Its CDP also consists of its intrahepatic cholangiocarcinoma (ICC) pivotal trial, scheduled to start enrollment by the end of this year.

Delcath Systems announced earlier this month that results of a multi-center retrospective analysis of the Company’s PHP® Therapy have been accepted for publication in the peer-reviewed Journal of Surgical Oncology. The study, Percutaneous Hepatic Perfusion with Melphalan in Uveal Melanoma: A Safe and Effective Treatment Modality in an Orphan Disease, was conducted by researchers from Moffitt Cancer Center in Tampa, Florida and the University Hospital Southampton in the UK. An abstract of the study was presented at the 12th Annual Regional Therapies International Symposium in Snowbird, Utah in February 2017.

Today, Delcath Systems announced that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma completed its pre-specified review of safety data for treated patients in the trial. The DSMB recommended that the study continue without modification. The FOCUS Trial is evaluating the efficacy, safety, as well as pharmacokinetics of Melphalan/HDS in comparison to best alternative standard of care in 240 patients with metastatic ocular melanoma (OM).

Delcath Systems, Inc. (DCTH), closed Tuesday's trading session at $0.0555, down 4.31%, on 15,128,514 volume with 906 trades. The average volume for the last 60 days is 2,975,814 and the stock's 52-week low/high is $0.0302/$626.50.

Proteo, Inc. (PTEO)

OTC Markets, Stockhouse, InvestorsHub, and Stockopedia reported on Proteo, Inc. (PTEO), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

A clinical stage drug development company, Proteo, Inc. is headquartered in Irvine, California. The Company’s intention is to develop, promote, and market pharmaceuticals and other biotechnology products. Its emphasis is on the development of anti-inflammatory treatments for rare diseases with significant unmet needs. A Nevada corporation, Proteo lists on the OTC Markets Group’s OTCQB.

Proteo has one wholly-owned subsidiary, Proteo Biotech AG, which is a German corporation located in Kiel. Proteo Biotech AG is a clinical stage pharmaceutical development company

Proteo’s lead product is Elafin. This is a soluble endogenous protein produced by the human body. Elafin is a natural inhibitor of the two tissue destroying enzymes, neutrophil elastase and proteinase-3.

Elafin inhibits the proteolytic enzymes elastase and proteinase 3, and also the endogenous vascular elastase (EVE). In a double-blind, randomized and placebo-controlled Phase I single dose escalating trial, Elafin was well tolerated by healthy human subjects. In two Phase II studies with patients undergoing surgery for esophageal cancer and with patients undergoing coronary artery bypass grafting the first-rate tolerability was confirmed.

Proteo is involved in five areas of preclinical development for Elafin. These areas comprise pulmonary arterial hypertension (PAH); ventilator-induced lung injury in premature babies; lung transplantation; vascular damages; and life-threatening infections.

In June of 2016, Proteo announced that its wholly-owned German subsidiary, Proteo Biotech AG, was awarded a BFEI grant from the German State of Schleswig-Holstein.

The grant has a volume of up to EUR 874,000 (roughly US$ 1 million). The grant will be used for the research and development (R&D) program to develop a new formulation of Proteo's lead compound Elafin.

Yesterday, Proteo and its wholly-owned subsidiary, Proteo Biotech AG, announced the publication of research results by Han et al. from Chongqing Medical University. The research results demonstrate that Elafin prevents inflammatory damage to the lung of newborn mice subjected to oxygen-rich gas.

Han et al. report that Elafin treatment suppressed the inflammatory response associated with aberrant elastin deposition after exposure to oxygen-rich gas. In addition, Elafin treatment improved distal airway development in the injured newborn lung.

Their conclusion is that the inhibition of elastase and TGF-β1 signaling observed after Elafin treatment may be a new therapeutic target for preventing oxygen-induced lung injury in neonates.

Proteo, Inc. (PTEO), closed Tuesday's trading session at $0.07, even for the day. The average volume for the last 60 days is 5,407 and the stock's 52-week low/high is $0.035/$0.08.

Weyland Tech, Inc. (WEYL)

DreamTeamNetwork, OTC Journal, and Wall Street Mover reported earlier on Weyland Tech, Inc. (WEYL), and today are highlighting the Company, here at the QualityStocks Daily Newsletter.

Weyland Tech, Inc. is a provider of mobile business applications. The focus of its CreateApp platform is on the Asia markets. Currently, Weyland Tech offers the CreateApp platform directly in Singapore, India (Jaipur), and the U.S.A. and Canada. The Company’s CreateApp platform is provided in 14 languages. The "CreateApp" platform enables SMBs (Small-Medium-Sized Businesses) to create a mobile application without the necessity of technical knowledge and background. Weyland Tech is based in Hong Kong.

The Company signed a Master Service Agreement (MSA) with Orient Asia Pacific Limited (OAP). This is for the Indonesia market. OAP is a software and digital technology consulting company. In September of 2016, Weyland Tech announced that it signed a strategic licensing agreement with BGT Corporation Public Company Limited (BGT), for the Thailand market.

At present, Weyland Tech offers a DIY (Do-it-Yourself) App builder through a 'white label' platform. It offers this via strategic partnerships in the EU (minus Russia, Turkey, Armenia, Azerbaijan); Malaysia; Hong Kong/South China; Indonesia; and North/Central/South America. It will offer this in Korea through IAM, Inc.

The Company’s partner in Indonesia, OAP, earlier signed an agreement to provide a stored-value 'top-up' application targeted at the 120 million adults living without access to traditional banking facilities. The design of the application is to be offered by way of major telecommunications providers in Indonesia.

OAP has started a pilot program to 20 communities in Indonesia. OAP will offer the community application to the other 500,000 communities across Indonesia upon success of the pilot.

Last month, Weyland Tech announced that it signed a new reseller agreement with HandsOn Systems. HandsOn Systems Chief Executive Officer, Mr. Geoff Farrugia, said, "We are excited to be bringing the CreateApp platform to our customers. Our existing platforms serve nine industries from transportation and logistics to inventory management and asset control. We will be offering CreateApp through our network to thousands of SMBs that will benefit from deploying their own mobile apps to engage their customers. CreateApp will allow them to deploy engaging mobile apps quickly. It's a win-win-win."

Last week, Weyland Tech announced that its upcoming mobile wallet, AtozPay, has entered beta. The Company has reached the point where the application itself has entered beta and the marketing team has started reaching out to customers.

Weyland Tech believes that its experienced team will permit the Company to move through the beta speedily and subsequently move ahead from the soft launch to fully live, soon. The AtozPay team has concentrated on app development. Meanwhile, Weyland Tech management has been working to lay the corporate infrastructure to commence formal operations.

Weyland Tech, Inc. (WEYL), closed Tuesday's trading session at $3.90, up 11.43%, on 14,009 volume with 34 trades. The average volume for the last 60 days is 3,377 and the stock's 52-week low/high is $2.70/$6.95.

Integrated BioPharma, Inc. (INBP)

StockMister, OTCPicks, HotShotStocks, Wall Street Mover, Zacks, The Stock Psycho, Top Gun, and AllPennyStocks reported earlier on Integrated BioPharma, Inc. (INBP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Integrated BioPharma, Inc. engages primarily in the manufacture, distribution, marketing, and sales of vitamins, nutritional supplements, and herbal products. Its customers are mainly in the United States, Luxembourg, and Canada. Integrated BioPharma develops, manufactures, and distributes, around the world, in excess of 130 products. The Company does so through several wholly-owned subsidiaries.

Integrated BioPharma formerly went by the name Integrated Health Technologies, Inc. Established in 1979, the Company is based in Hillside, New Jersey. Integrated BioPharma lists on the OTC Markets.

Integrated Biopharma’s companies include AgroLabs, Inc., Chem International, IHT Health Products, Inc., Manhattan Drug Company, and Vitamin Factory. Integrated BioPharma operates via three segments. These are Contract Manufacturing, Branded Proprietary Products, and Other Nutraceutical Businesses.

AgroLabs manufactures and markets healthful nutritional products under the Naturally Noni, Naturally Pomegranate, Naturally Aloe, and Naturally Mangosteen brands. Additionally, AgroLabs distributes internationally, in Canada, Germany, Japan, Korea, Mexico, Taiwan and the United Kingdom (UK). Integrated BioPharma’s Chem International offers a broad assortment of Roche Vitamins' food and cosmetic products.

The Company’s Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. Its Branded Proprietary Products segment distributes healthful nutritional products for sale through mass market, grocery, drug, as well as vitamin retailers.

The Other Nutraceutical Businesses segment sells private label vitamin and nutritional supplement products, and healthful nutritional products through the Internet. In addition, this segment distributes fine natural botanicals. This includes multi minerals and raw materials. Moreover, the Other Nutraceutical Businesses segment provides warehousing and fulfilment services.

Integrated BioPharma’s Vitamin Factory sells nutritional supplements directly to the consumer by way of mail order catalogs and over the Internet. Vitamin Factory’s product categories are dietary supplements, liquid items, sports supplements, and skincare supplements.

Manhattan Drug Company provides vitamins and nutritional formulations. It engages in the manufacturing of tablets, capsules, or blends; packaging and labeling in bulk; help in product registration worldwide, and distribution of finished product. Also, Manhattan Drug Company engages in analytical and microbiological testing via its in-house laboratories.

Integrated Biopharma’s IHT Health Products sells and distributes fine chemicals. These include science-based proprietary products and value added formulations. IHT sells and distributes these to the nutritional, pharmaceutical, food, and cosmetic industries. IHT products include vitamins, amino acids, herbal extracts, Over-the-Counter (OTC) pharmaceuticals, excipients, and unique patented products.

Integrated BioPharma, Inc. (INBP), closed Tuesday's trading session at $0.186192, up 14.11%, on 156 volume with 1 trade. The average volume for the last 60 days is 7,553 and the stock's 52-week low/high is $0.125/$0.34.

TransAKT Ltd. (TAKD)

OTC Markets, Stockhouse, Barchart, and The Street reported on TransAKT Ltd. (TAKD), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

TransAKT Ltd. is a manufacturer of highly unique agricultural equipment used to grow a broad array of vegetables and fruit employing simulated sunlight from LED lamps in an indoor proprietary hydroponic system. In addition, the Company is an international distributor of LED lighting products centered on serving the fastest developing market of commercial, hospitality, and outdoor lighting. OTCQB-listed, TransAKT is based in Hong Kong.

The Company’s commitment is to helping business owners protect the environment through superior energy efficiency - replacing current non-energy-efficient light sources with energy-efficient light sources. Additionally, TransAKT is focusing on eliminating the use of chemical fertilizers and pesticides utilizing the latest hydroponic agricultural technology and pure nutrients.

The nutrient solutions used in production with its hydroponic systems leave no heavy metal and chemical residues. TransAKT’s product line includes commercial production and home growing systems.

TransAKT’s wholly-owned subsidiary is Vegfab Agriculture Technology Co., Ltd. Vegfab was created in 2010 by a team of ecologically minded semiconductor specialists knowledgeable about LED materials.

Furthermore, TransAKT is looking for opportunities to develop a BIO-technology business in China. The Company says that the cordyceps business is one project with the greatest potential. It has engaged a team of approximately 10 experts in BIO technology engineering to develop an extended product mix. These products will debut in China in the next few years.

Vegfab’s product line includes systems for commercial production and a home growing system, which enables families to grow safe and clean fruit and vegetables in their homes. Vegfab products are the subject of numerous patents. These include ones for vertically wall-mounted LED lights, and ventilation systems for grow boxes.

Vegfab provides complete growing systems consisting of proprietary simulated sunlight LED boards; growing racks in diverse configurations for commercial and residential applications; environment control and plant nutrition control components; portable work tables and ladders; fruit and vegetable seeds and nutrition products; and vegetables.

Vegfab’s vegetable production factory in Yangmei City, Taiwan is the only mass production facility for vegetables in Taiwan. The facility utilizes innovative technology to produce exceptional yields from a very small space. Production is very efficient through the use of simulated sunlight from LED lamps, up to 85 percent automated.

TransAKT Ltd. (TAKD), closed Tuesday's trading session at $0.06, down 17.36%, on 161 volume with 3 trades. The average volume for the last 60 days is 3,055 and the stock's 52-week low/high is $0.02/$0.2113.

graphic

The QualityStocks
Company Corner

graphic
graphic

PotNetwork Holdings Inc. (POTN)

The QualityStocks Daily Newsletter would like to spotlight PotNetwork Holdings Inc. (POTN). Today, PotNetwork Holdings Inc. closed trading at $0.0643, up 7.17%, on 9,305,975 volume with 448 trades. The stock’s average daily volume over the past 60 days is 3,481,943, and its 52-week low/high is $0.002/$0.0995.

PotNetwork Holding, Inc. (OTC Pink: POTN) announced today, it’s wholly owned subsidiary, Diamond CBD, Inc., has reported its revenues for November. Exceeding $1.6 million, management enters the final stretch of 2017 having developed a strong and consistent trend for solid growth. With continual month over month advancement, Diamond CBD’s premium quality products have bolstered in popularity throughout the year and widely captured the attention of celebrities and distinguished media sources nationwide.

PotNetwork Holdings Inc. (POTN), based in Fort Lauderdale, Florida, is a holding company. The company's First Capital Venture Co. subsidiary is the owner of Diamond CBD, Inc., a producer of widely-distributed CBD hemp extracts and the primary operating entity of PotNetwork Holdings.

Diamond CBD is made up of chemists and other scientists focused on developing and producing very high-quality CBD oil over a broad range of products, based upon a thorough understanding of the various natural molecules found in hemp and their particular properties. All products are made with federally legal cannabidiol (CBD), and are available in hundreds of flavors and sizes. The company emphasizes a dedication to 100% natural lab-tested CBD ingredients, with a carefully monitored process all the way from the source farm, through production, and final delivery to retail shelves.

PotNetwork, through Diamond CBD, delivers products to all 50 states, as well as internationally, and controls 15 CBD brands. The company lists the following product brands:

  • Diamond CBD Gummies - Diamond CBD branded edible gummies made from crystal isolate. Available in a variety of flavors and gummy styles, including rainbow bites, mini fruit, gummy worms, sour snakes, and more.
  • Chill Gummies - Chill gummies are more robust than its counterpart, the "Relax" gummy line. Chill Gummies are edible CBD gummies available in a wide variety of flavors, strengths, and styles including gummy bears, sour snakes, rainbow bites, watermelon slices, sour snakes, rainbow bites, peanut butter chocolate, ocean gummies, gummy worms, gummy rings and more.
  • CBD Liquid Gold - CBD Liquid Gold is derived from naturally grown industrial hemp plants, certified by USA labs and then carefully mixed with a patent-pending (non-PG) all-natural base formulation.
  • Blue CBD - Blue CBD Crystal Isolate is a high-end vapor liquid and oral drop infused with premium CBD rich hemp oil. CBD liquids are Premium Gold quality and test at a 7X higher concentration.
  • Relax Gummies - Relax Gummies give a lighter effect of CBD with some natural flavors in comparison to its counterpart Chill Gummies. Relax Gummies are perfect for anyone with a sweet tooth that's looking for a lighter effect without sacrificing quality or taste.
  • Premium Hemp Liquid Pet - CBD For Pets is a new and refreshing product from Diamond CBD for all the millions of pets out there. It is an organic product and also has unique flavors in it.
  • CBD Re-Leaf - Disposable, long-lasting, and ready to Use CBD Re-leaf vaping pens available in a variety of flavors. Easily take CBD anywhere on the go.
  • Relax Extreme CBD - Relax Extreme CBD Oil provides a high-quality, high-strength dose of CBD through oral drops. It is very easy to use and works instantly. Simply place a drop under the tongue. Available in various strengths.
  • CBD Double Shot - CBD Double Shots are specifically designed for one-time use. Easily squeeze the package in your mouth and swallow; it's that simple. Take it anywhere you go. Relaxation is now conveniently in your pocket. Drinkable CBD shots provide a quick boost of relaxation on the go. Available in various flavors.
  • Chill Pill - CBD infused capsules available in various strengths. Relax, take a Chill Pill.

Over 1.2 million people currently use cannabis, including CBD products, for medical application, including cancer, epilepsy, and depression. By sourcing hemp outside the U.S., the company avoids current federally-based legal problems involved in growing cannabis domestically. In the meantime, PotNetwork Holdings continues to target a large and rapidly developing cannabis market, expanding from $6.5 billion in 2016, to an expected $30 billion in 2021 (Forbes), and $50 billion in 2026 (Bloomberg). The cannabidiol market alone is projected to reach $2.1 billion in 2020, a 700% increase from 2015. PotNetwork Holdings Inc. plans to expand its subsidiaries as well as make strategic acquisitions. Disclaimer

PotNetwork Holdings Inc. Company Blog

PotNetwork Holdings Inc. News:

Surpassing $1.6 Million in Revenues for November, PotNetwork Holding, Inc. Prepares to Conclude Record Breaking Year

PotNetwork Holding Acclaimed as One of Five Notable CBD Revolution Industry Leaders on Huffington Post

PotNetwork Holding, Inc. PCOAB Concludes Initial Auditing Requirement for Up-List

InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals, Inc. (IMLFF). Today, InMed Pharmaceuticals, Inc. closed trading at $0.64, off by 9.87%, on 1,937,755 volume with 1,070 trades. The stock’s average daily volume over the past 60 days is 929,958, and its 52-week low/high is $0.1104/$0.9611.

CannabisNewsWire Editorial Coverage: Relatively insulated from economic cycles, the innovation of today’s biotech companies puts them in a position to potentially deliver outsized returns regardless of overall conditions. Medicinal cannabis, a key sector in this industry, is currently driving the largest returns, and it is on pace to exceed US$50 billion in revenues by 2025. As more investors are noticing, positive news continues to flow into the sector in terms of new drug applications, product approvals and pipeline updates. For InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), a preclinical-stage biopharmaceutical company at the vanguard of cannabinoid-based bio-pharmacology, market awareness of the company’s drug development pipeline and biosynthesis technology has led to gains of more than 400% over the last year.

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed’s website, this type of bioinformatics assessment represents “significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease.”

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company’s proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company’s pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as “The Worst Disease You’ve Never Heard Of,” EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed’s second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company’s management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company’s current market value totaling more than $2.9 billion. Disclaimer

InMed Pharmaceuticals, Inc. Company Blog

InMed Pharmaceuticals, Inc. News:

Biotech Market Banking on Big Cannabis Returns

NetworkNewsWire Announces Publication Discussing the Production of Quality Cannabinoids with Therapeutic Potential

The Therapeutic Potential of Pharmacologically Active Cannabinoids

Petrogress, Inc. (PGAS)

The QualityStocks Daily Newsletter would like to spotlight Petrogress, Inc. (PGAS). Today, Petrogress, Inc. closed trading at $0.03246, off by 5.91%, on 399,895 volume with 37 trades. The stock’s average daily volume over the past 60 days is 436,762, and its 52-week low/high is $0.0161/$0.072.

Petrogress, Inc. (OTC:PGAS) today announces that its Petrogress Int’l, LLC (“PIL”) subsidiary has entered into a Memorandum of Understanding (“MOU”) with EDT Agency Services, Ltd. (“EDT Offshore”) to combine the companies’ operations at the Port of Limassol and additional port facilities in Cyprus. The MOU covers shorebase and offshore support services from the Port of Limassol, as well as future developments at Vassiliko Energy Port, where the Cyprus Port Authority has announced plans for a US$300 million industrial and energy harbor.

Petrogress, Inc. (PGAS) founded in 2009, owns and operates a fleet of tankers from its base in the historic Port of Piraeus, Greece, through a series of Marshall Islands subsidiaries. The company is an international merchant of petroleum products which includes reliably marketing and trading crude oil, distillates, and refined products off the coast of West Africa. The company also operates service and shipping facilities at the Port of Limassol in Cyprus and the Port of Tema, Greater Accra, in Ghana. It is actively seeking expansion opportunities, including in operating and developing natural gas production and transmission facilities along with LNG processing in the U.S., refinery operations in north and west Africa, and the transport and sales of LNG in Europe.

Petrogress has created a diversified revenue stream, giving it a significant advantage over similar companies working in the oil and gas shipping arena. A case in point is the recent formation of "PG Cypyard & Offshore Service Terminal Ltd. ("Cypyard"), through the company's wholly owned subsidiary, Petrogress Int'l, LLC. Cypyard is concluding negotiations for an operations and management agreement covering ports in Hellenic Cyprus, including the Port of Limassol, directly with the Cyprus Ports Authority. Current plans include a long-term lease with renewal options covering all in-place port facilities, including floating dock and dry dock areas, with cranes and scaffolding, construction and repair workshops and storage, and complete on-site administrative and office space.

"I think the opportunities there are great, and dealing directly with partners in government has numerous benefits," said Christos P. Traios, president of Petrogress Inc. in a news release announcing the venture. The recent appointment of two industry experts to the Petrogress Advisory Board is expected to help the company capitalize on future growth opportunities while simultaneously developing a comprehensive U.S. and international lobbying and government outreach program to facilitate business plans in the U.S., European Union and Africa.

Additional Petrogress Inc. subsidiaries are:

  • Petrogress Co. Ltd., an international merchant of petroleum products that combines regional market knowledge with over 20 years of excellent shipping experience.
  • Petrogress Co. Ltd., an international merchant of petroleum products that combines regional market knowledge with over 20 years of excellent shipping experience.
  • Petrogress Oil & Gas Energy Inc., which has expansion plans through a supply of liquified natural gas located in the oil fields of Texas with an eye toward exporting LNG to Mediterranean markets.

Petrogress continues to "adjust its sails" in order to meet new challenges. Opportunities include upstream oil resources and exploration, the addition of more product fleet carriers, downstream movement of petroleum products from refineries to finished sales, and sea transportation of liquified natural gas. A closely followed economist, Jim O'Neill, states that oil prices could spike more than 25% in the next year. O'Neill, now an economics professor at the University of Manchester, says the market is finally waking up to the fact that global economic growth is gaining momentum and likely expanding at 4 percent or higher. That means there will be more demand for oil, the article states, which translates into brighter days ahead for companies like Petrogress. Disclaimer

Petrogress, Inc. Company Blog

Petrogress, Inc. News:

Petrogress, Inc. Announces Joint Venture with International Marine Fleet & Offshore Support Provider

NetworkNewsWire Releases Exclusive Audio Interview with Petrogress Inc. (PGAS)

Petrogress, Inc. (PGAS) is “One to Watch”

LottoGopher Holdings Inc. (OTCQB:LTTGF) (CSE:LOTO) (FRA:2LG)

The QualityStocks Daily Newsletter would like to spotlight LottoGopher Holdings Inc. (LTTGF). Today, LottoGopher Holdings Inc. closed trading at $0.13, up 17.97%, on 241,390 volume with 26 trades. The stock’s average daily volume over the past 60 days is 143,043 and its 52-week low/high is $0.0805/$0.50.

LottoGopher Holdings Inc. (LTTGF) is a new lottery messenger service that provides its subscribers with the security of ordering and managing the legal purchase of state lottery tickets online using debit and credit cards. LottoGopher makes it simple for users to keep track of tickets and winnings. Members have exclusive access to strategies, alerts, lottery news and can play alone with a single ticket or join online public or private groups to pool winnings.

LottoGopher is transforming the lottery buying experience, which has historically meant taking the time and spending the gas money to drive to a retail location, then stand in line to buy via cash only and redeem tickets. LottoGopher's uniquely online messenger service streamlines the experience of taking a shot at the lottery and makes it much more convenient and access to electronic payment, otherwise not permitted in CA. While only California residents at this time can play Mega Millions, SuperLotto Plus and Powerball through LottoGopher.com, expansion plans are in the works to allow internet-savvy residents in 22 other states with legal lotteries to have the same advantages of purchasing tickets online.

LottoGopher also enjoys a strategic business relationship with Lottoland, ranked in the Financial Times' FT1000 Report as one of Britain's Top 30 fastest growing companies and as the second ranked gaming company in Europe. Since launching in 2013, Lottoland has rapidly become a world leader in the online lottery sector with nearly $357 million (U.S. dollars) in annual sales.

LottoGopher's currently integrated support systems include a mobile friendly platform; automated email follow-up system to capture, score and remarket to email address leads; social media listening and outreach; utilization of Google Analytics tools; one-time promotional offers across multiple platforms; main and backup credit card processing accounts; and focus on customer service.

Customers of LottoGopher pay a subscription fee to use the service, much like Netflix, Amazon Prime or Dollar Shave Club. After selecting their subscription plan, users pay the same price per ticket as if purchasing from a retail, brick-and-mortar location. LottoGopher's team then secures the selected tickets from a lottery retailer partner. User account balances are updated after a drawing, which makes it impossible for a member to "lose" a winning ticket.

The company's target market includes the 80 million U.S. consumers already buying lottery tickets who typically purchase products online. Offering a far more convenient way to play the lottery via an intuitive platform, LottoGopher is well positioned to disrupt this multi-billion dollar industry. Disclaimer

LottoGopher Holdings Inc. Blog

LottoGopher Holdings Inc. News:

LottoGopher Holdings Inc. Plans to Develop and Launch 'Lottery Blockchain'

NetworkNewsWire Announces Publication Harnessing the Power of Celebrity Endorsements

NetworkNewsWire Releases Exclusive Audio Interview with LottoGopher Holdings Inc.

RJD Green Inc. (RJDG)

The QualityStocks Daily Newsletter would like to spotlight RJD Green Inc. (RJDG). Today, RJD Green Inc. closed trading at $0.0104, up 13.04%, on 357,100 volume with 21 trades. The stock’s average daily volume over the past 60 days is 2,016,876, and its 52-week low/high is $0.0037/$0.029.

RJD Green Inc. (RJDG) is a holding company with a focus on acquiring and managing assets and companies in three divisions. These initial high-growth enterprise opportunities offer diversity in separate recession resistant markets. The division holdings include:

  • RJD Green Healthcare Services – provides services to reduce cost and enhance management and operational capabilities in the healthcare sector.
  • Earthlinc Environmental Services – provides green environmental services and technologies.
  • Silex Holdings – acquires specialty construction and industrial manufacturing assets.

RJD Green Healthcare Services, through its wholly owned subsidiary IOSOFT Inc., provides proprietary software and IT support for medical billing, healthcare claims adjudication, and electronic payments between healthcare payers and providers. IOSOFT's unique payment technologies and services or software can be integrated with existing systems of healthcare payers such as Blue Cross, Aetna, CIGNA and others. IOSOFT provides targeted offerings for healthcare providers, provider networks, physicians and hospitals, and clearinghouse companies.

Earthlinc Environmental Solutions was formed to bring forward green-applied technologies and offer environmental services with a focus on North America. The division's first acquisition, Animal Waste Management, is launching operations of a patented, fully developed technology for processing waste produced on commercial poultry and hog farms. Development of this technology was supported by the University of Arkansas and the Missouri Department of Natural Resources. This important technology improves the farm's productivity and is competitively priced with the current expense of handling waste removal at these sites.

The company's third division – Silex Holdings Inc. – was formed to acquire and manage high-growth assets and business enterprises in the industrial and construction specialty services sectors. With its first acquisition of Silex Interiors, a manufacturer, distributor and installer of counter tops, cabinets and related kitchen and bath products, the division is poised to expand into major national markets through internal expansion, acquisition and franchising. The company is modeled to operate a minimum of four corporately owned locations with 12 to 18 franchise locations nationwide.

RJD Green seeks to participate as owners, partners or in joint ventures in a wide range of business enterprises. The company's goal of creating a successful, enjoyable business enterprise for its company team and staff, along with its business partners and investors, is paired with the goal of maximizing the business potential of the enterprise by enhancing profits and the quality of the company. Disclaimer

RJD Green Inc. Company Blog

RJD Green Inc. News:

RJD Green, Inc. Updates Progression of Animal Waste Management and 2017 10K Filing

RJD Green Inc. Appoints Director

RJD Green Inc. Subsidiary, IOSOFT, Discusses Contracts Procured and Revenue Expectations

Tapinator, Inc. (TAPM)

The QualityStocks Daily Newsletter would like to spotlight Tapinator, Inc. (TAPM). Today, Tapinator, Inc. closed trading at $0.175423, up 7.95%, on 83,272 volume with 19 trades. The stock’s average daily volume over the past 60 days is 107,258 and its 52-week low/high is $0.0711/$0.2419.

Tapinator, Inc. (TAPM) is a developer and publisher of mobile games on the iOS, Google Play and Amazon platforms. The Company's portfolio includes over 300 mobile gaming titles generating hundreds of thousands of daily player downloads that provide predictable and attractive returns through the sale of branded advertisements and consumer app store transactions. Tapinator, based in New York and with product development teams located throughout the world, was founded in 2013 by a visionary team that has been building mobile games and applications since 2007 and has achieved multiple successful exits.

Tapinator's business strategy includes the creation of a select number of best-in-class Full-Featured Games, such as ROCKY™ and Solitaire Dash, which provide game players with more in-depth, unique content that supports long-term retention and generates higher investment returns. The Full-Featured Games model creates the potential for sustainable $100+ million franchise-type games that have product lifespans of at least five years. Tapinator uses a proprietary set of dynamic development and marketing processes factored upon gaming category, estimated player retention and projected player profitability.

Recent successful launches of two new Full-Featured titles – Big Sport Fishing 2017 and Dice Mage 2 – were recognized on the Apple iOS platform as "New Games We Love." During the game's first seven days after global release, Big Sport Fishing 2017 received well over 520,000 player downloads. Four new titles, ColorFill, Divide & Conquer, Shadowborne and Fusion Heroes, are in the pipeline for release in Q4 2017 and Q1 2018 as well. The formula for these game combines proven gameplay elements with best-in-class monetization systems, supplemented by Tapinator's strong creative team of developers, strategists and product specialists. The company's Rapid-Launch Games division also saw increasing player interest recently with the launch of Fidget Spinner Superhero and Scary Shark Evolution 3D.

Tapinator's diversified revenue sources includes 54 percent from advertising placed within its mobile games and 46 percent from consumer app store purchases. The Company limits advertising placements to between game levels and also runs rewarded video ad units that are tied directly into the game's currency. Tapinator's portfolio includes more than 300 active titles, with no single game accounting for more than 25 percent of total revenues during the first half of 2017.

As Tapinator looks toward the future, opportunities in Virtual Reality (VR) and Augmented Reality (AR) show great promise. The company has released several prototype VR games to gather data before pursuing a more significant VR product. Recent market reports suggest that the VR industry will hit $30 billion by 2020 and the AR industry will surpass that with a projected $120 billion. Tapinator also plans to pursue publishing transactions that leverage its network, platform relationships and operational excellence. Significant opportunities for expanding Tapinator's gaming IP to new platforms such as Steam and leading messaging apps are also on the horizon. The company is targeting a 30+ percent annual bookings growth target for 2017-2019. Disclaimer

Tapinator, Inc. Blog

Tapinator, Inc. News:

NetworkNewsWire Announces Publication on M&A in the Mobile Gaming Industry

Mobile Gaming Acquisitions on Pace to Boom in 2018

Tapinator Announces Full-featured Games Pipeline Through Q1 2018

Medical Cannabis Payment Solutions (REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG). Today, Medical Cannabis Payment Solutions closed trading at $0.0749, up 8.41%, on 701,079 volume with 65 trades. The stock’s average daily volume over the past 60 days is 512,973, and its 52-week low/high is $0.0161/$0.20.

Medical Cannabis Payment Solutions (REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company's state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company's unique "StateSourced" proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven't been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin's cryptocurrency ($Weed) with Medical Cannabis Payment Solutions' StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

"We've completed our transition from development stage to revenue stage," says Roberts. "We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases."

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry. Disclaimer

Medical Cannabis Payment Solutions Company Blog

Medical Cannabis Payment Solutions News:

Medical Cannabis Payment Solutions (REFG) Engages NetworkNewsWire for Corporate Communications Solutions

Medical Cannabis Payment Solutions to Launch New Website and Portal, Completes Rebrand of its Product Offering

Medical Cannabis Payment Solutions (REFG) Integrates Cryptocurrency Payment Options

graphic

Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters

graphic

1.

MarketClub Analysis
(CCIH) +195.51%

2.

PoliticsAndMyPortfolio
(BEGI) +138.97%

3.

StockMarketWatch
(PFNX) +62.50%

graphic
By The Numbers Charts
QualitystockTwits

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors
















 

The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.

 

About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251